Co-Editor in Chief of the journal ONCOLOGY discusses how potential shortages in oncology clinicians could influence the treatment of cancer going forward.
Julie M. Vose, MD, MBA
Co-Editor in Chief
Professor, Internal Medicine
Chief of Hematology & Oncology, Department of Internal Medicine
University of Nebraska Medical Center College of Medicine
Associate Director of Clinical Research
Fred and Pamela Buffet Cancer Center
Omaha, NE
Julie M. Vose, MD, MBA, is the Neumann M. and Mildred E. Harris professor and the chief of the Division of Oncology/Hematology in the Department of Internal Medicine at University of Nebraska Medical Center (UNMC). Vose graduated from Medical School at UNMC, completed her internal medicine residency as well as a Chief Resident year, followed by a Hematology/Oncology Fellowship at UNMC, and has been on faculty since 1990. Vose is an internationally known leading expert in the treatment of patients with Hodgkin lymphoma, non-Hodgkin lymphoma (NHL), and chronic lymphocytic leukemia. She is actively involved in many novel clinical trials for lymphoma including targeted agents, monoclonal antibodies, and cellular therapy. Vose has been recognized for her NHL research on a national and international level through research awards and invited lectureships worldwide.
Advertisement
ONCOLOGY co–Editor-in-Chief Julie M. Vose, MD, MBA, details how underrepresentation of racial and ethnic minorities in clinical trials negatively impacts the medical community and calls for greater inclusion by removing some barriers to participation.
Unprecedented efforts from researchers and pharmaceutical engineers have brought about safe, effective vaccines, in record development times; now the focus must be on a federally coordinated program to administer those injections in the most efficient manner possible.
The 2020 American Society of Hematology Meeting and Exposition included several exciting presentations and promising data for patients with various hematologic malignncies.
Accurate and well maintained patient-level data is needed to gather and formulate real-world evidence that is necessary to optimize existing treatment and shape future treatment for patients with hematological malignancies.
ONCOLOGY® Editor in chief Julie M. Vose, MD, MBA discusses both the positive and negative changes that have come about because of the COVID-19 pandemic.
The first episode of CancerNetwork's podcast Oncology Peer Review On-The-Go explores disparities in cancer care treatment among minorities and the significance of a representative sample in clinical trials.
Editor in chief Julie M. Vose, MD, MBA discusses the difficulties of treating and caring for patients with cancer during the COVID-19 pandemic.
The lymphoma expert, from the University of Nebraska Medical Center, spoke about how the COVID-19 pandemic has affected her facility and their ability to perform cancer care.
Advertisement
Advertisement
